BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 2019;3:851-61. [PMID: 30885996 DOI: 10.1182/bloodadvances.2018025874] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 29.5] [Reference Citation Analysis]
Number Citing Articles
1 Li S, He J, Zhang X, Cai Y, Liu J, Nie X, Shi L. Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.966182] [Reference Citation Analysis]
2 Cortes J, Silver RT, Kantarjian HM. Chronic Myeloid Leukemia. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm116.pub2] [Reference Citation Analysis]
3 Yoshifuji K, Sasaki K. Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. Front Oncol 2022;12:1021662. [DOI: 10.3389/fonc.2022.1021662] [Reference Citation Analysis]
4 Masbuchin AN, Widodo, Rohman MS, Liu P. The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system? Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.986570] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Mehra N, Varmeziar A, Chen X, Kronick O, Fisher R, Kota V, Mitchell CS. Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Cancers 2022;14:4686. [DOI: 10.3390/cancers14194686] [Reference Citation Analysis]
6 Umezawa Y, Sasaki K. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol 2022. [PMID: 36087226 DOI: 10.1007/s12185-022-03431-8] [Reference Citation Analysis]
7 Yu B, Osman AE, Sladojevic N, Prabhu N, Tai H, Chen D, Perla G, Park L, Larson RA, Liao JK. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC: CardioOncology 2022;4:371-383. [DOI: 10.1016/j.jaccao.2022.06.004] [Reference Citation Analysis]
8 Tsuda M, Hirata A, Tokunaga S, Masuda T, Haji S, Kimura D, Nojiri C, Nakashima Y, Shiratsuchi M, Kato K, Miyamoto T, Akashi K, Nakashima N, Ogawa Y. Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia. Int J Hematol 2022. [PMID: 35932399 DOI: 10.1007/s12185-022-03433-6] [Reference Citation Analysis]
9 Lopina N, Dmytrenko I, Hamov D, Lopin D, Dyagil I. A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. Cureus. [DOI: 10.7759/cureus.25766] [Reference Citation Analysis]
10 Senapati J, Sasaki K. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers 2022;14:2533. [DOI: 10.3390/cancers14102533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lipton JH, Brümmendorf TH, Gambacorti-passerini C, Garcia-gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Conte C, Vayr F, Pajiep MC, Despas F, Huguet F, Mestre ML, Gauthier M, Herin F. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study. Support Care Cancer 2022. [PMID: 35304631 DOI: 10.1007/s00520-022-06968-w] [Reference Citation Analysis]
13 Chen K, Ruan Y, Tian K, Xiong P, Xia N, Li J, Huang W, Cao F, Chen Q. Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis. Front Oncol 2022;12:841546. [PMID: 35223524 DOI: 10.3389/fonc.2022.841546] [Reference Citation Analysis]
14 Sicuranza A, Ferrigno I, Abruzzese E, Iurlo A, Galimberti S, Gozzini A, Luciano L, Stagno F, Russo Rossi A, Sgherza N, Cattaneo D, Zuanelli Brambilla C, Marzano C, Fava C, Mulas O, Cencini E, Santoni A, Sammartano V, Gozzetti A, Puccetti L, Bocchia M. Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). Front Oncol 2022;12:835563. [PMID: 35178353 DOI: 10.3389/fonc.2022.835563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chen W, Du B, Liu K, Yu Z, Wang X, Yang P. Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review. BMC Cardiovasc Disord 2022;22. [DOI: 10.1186/s12872-022-02504-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Andretta E, Costa C, Longobardi C, Damiano S, Giordano A, Pagnini F, Montagnaro S, Quintiliani M, Lauritano C, Ciarcia R. Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy. Front Oncol 2021;11:801779. [PMID: 34993151 DOI: 10.3389/fonc.2021.801779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, Mauro M, Croce K, Berman E, Deininger M, Hochhaus A, Pinilla-Ibarz J, Nicolini F, Kim DW, DeAngelo DJ, Kantarjian H, Xu J, Hall T, Srivastava S, Naranjo D, Cortes J. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol 2022;15:1. [PMID: 34991679 DOI: 10.1186/s13045-021-01221-z] [Reference Citation Analysis]
18 Scott SS, Greenlee AN, Schwendeman EJ, Mohammad SJ, Naughton MT, Matzko A, Diallo M, Stein M, Revan R, Zaramo TZ, Shimmin G, Tarun S, Ferrall J, Ho TH, Smith SA. Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. Cardiovascular Signaling in Health and Disease 2022. [DOI: 10.1007/978-3-031-08309-9_4] [Reference Citation Analysis]
19 Mauro MJ. Lifelong TKI therapy: how to manage cardiovascular and other risks. Hematology Am Soc Hematol Educ Program 2021;2021:113-21. [PMID: 34889360 DOI: 10.1182/hematology.2021000239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Khouri C, Mahé J, Caquelin L, Locher C, Despas F. Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapie 2021:S0040-5957(21)00242-0. [PMID: 34895753 DOI: 10.1016/j.therap.2021.11.004] [Reference Citation Analysis]
21 Cortes J, Pavlovsky C, Saußele S. Chronic myeloid leukaemia. Lancet 2021;398:1914-26. [PMID: 34425075 DOI: 10.1016/S0140-6736(21)01204-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
22 Amir M, Javed S. A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs. Front Genet 2021;12:742802. [PMID: 34745216 DOI: 10.3389/fgene.2021.742802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Douvas MG, Riegler LL. Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 2021. [PMID: 34735688 DOI: 10.1007/s11899-021-00657-x] [Reference Citation Analysis]
24 Matsushita M. Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells. Cancers (Basel) 2021;13:5435. [PMID: 34771599 DOI: 10.3390/cancers13215435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France. Front Oncol 2021;11:675609. [PMID: 34660261 DOI: 10.3389/fonc.2021.675609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Chen MT, Huang ST, Lin CW, Ko BS, Chen WJ, Huang HH, Hsiao FY. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study. Oncologist 2021;26:974-82. [PMID: 34418220 DOI: 10.1002/onco.13944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group. Intern Med 2021;60:2207-16. [PMID: 33612681 DOI: 10.2169/internalmedicine.6620-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yang YC, Huang RY, Tsai HJ, Li PC, Yang YH, Hsieh KP. Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study. Eur J Prev Cardiol 2021:zwab043. [PMID: 34179961 DOI: 10.1093/eurjpc/zwab043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Perrone V, Giacomini E, Andretta M, Arenare L, Cillo MR, Latini M, Mecozzi A, Pagliaro R, Vercellone A, Degli Esposti L. Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia. Ther Clin Risk Manag 2021;17:617-22. [PMID: 34135589 DOI: 10.2147/TCRM.S309342] [Reference Citation Analysis]
30 Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, Sweet K, Pinilla-Ibarz J. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv 2020;4:530-8. [PMID: 32045474 DOI: 10.1182/bloodadvances.2019000268] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 33.0] [Reference Citation Analysis]
31 Adnan-Awad S, Kankainen M, Mustjoki S. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma 2021;:1-15. [PMID: 33944660 DOI: 10.1080/10428194.2021.1894652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
32 Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol 2021;113:624-31. [PMID: 33782818 DOI: 10.1007/s12185-021-03127-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
33 Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol 2021;113:632-41. [PMID: 33772728 DOI: 10.1007/s12185-021-03126-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
34 Oehler VG. First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia? Hematology Am Soc Hematol Educ Program 2020;2020:228-36. [PMID: 33275713 DOI: 10.1182/hematology.2020000108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
35 Smith SM, Hijiya N, Sakamoto KM. Chronic Myelogenous Leukemia in Childhood. Curr Oncol Rep 2021;23:40. [PMID: 33718985 DOI: 10.1007/s11912-021-01025-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bencomo-Alvarez AE, Rubio AJ, Olivas IM, Gonzalez MA, Ellwood R, Fiol CR, Eide CA, Lara JJ, Barreto-Vargas C, Jave-Suarez LF, Nteliopoulos G, Reid AG, Milojkovic D, Druker BJ, Apperley J, Khorashad JS, Eiring AM. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene 2021;40:2697-710. [PMID: 33712704 DOI: 10.1038/s41388-021-01732-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
37 Schafer AI. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2021;35:305-24. [PMID: 33641871 DOI: 10.1016/j.hoc.2020.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Wang Z, Jiang L, Yan H, Xu Z, Luo P. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies. Expert Rev Clin Pharmacol 2021;14:445-56. [PMID: 33618586 DOI: 10.1080/17512433.2021.1894129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
39 Ameri P, Tini G, Spallarossa P, Mercurio V, Tocchetti CG, Porto I. Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. Br J Clin Pharmacol 2021;87:3690-8. [PMID: 33620103 DOI: 10.1111/bcp.14793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol 2021;96:241-50. [PMID: 33180322 DOI: 10.1002/ajh.26047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
41 Deloughery TG. Bleeding and Thrombosis. Oncologic Emergency Medicine 2021. [DOI: 10.1007/978-3-030-67123-5_37] [Reference Citation Analysis]
42 Wu MD, Moslehi JJ, Lindner JR. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arterioscler Thromb Vasc Biol 2021;41:3-10. [PMID: 33275447 DOI: 10.1161/ATVBAHA.120.314694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Cortes J. How to manage CML patients with comorbidities. Hematology Am Soc Hematol Educ Program 2020;2020:237-42. [PMID: 33275749 DOI: 10.1182/hematology.2020006911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Cortes J. How to manage CML patients with comorbidities. Blood 2020;136:2507-12. [PMID: 33236757 DOI: 10.1182/blood.2020006911] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
45 Serrao A, Scalzulli E, Fiori L, Di Prima A, Breccia M, Chistolini A. Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Clin Drug Investig 2020;40:1177-81. [DOI: 10.1007/s40261-020-00980-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Varga A, Tilea I, Petra DN, Tilinca MC, Gliga ML, Demian S. Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors-A Single-Centre Retrospective Study. J Clin Med 2020;9:E3269. [PMID: 33053860 DOI: 10.3390/jcm9103269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Mukai M. 15. Cancer-associated Thrombosis and Onco-Cardiology. J Jpn Soc Intern Med 2020;109:1960-1967. [DOI: 10.2169/naika.109.1960] [Reference Citation Analysis]
48 Zeng P, Schmaier A. Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis. Int J Mol Sci 2020;21:E6556. [PMID: 32911643 DOI: 10.3390/ijms21186556] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
49 Siragusa M, Oliveira Justo AF, Malacarne PF, Strano A, Buch A, Withers B, Peters KG, Fleming I. VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetes. Cardiovasc Res 2021;117:1546-56. [PMID: 32653904 DOI: 10.1093/cvr/cvaa213] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
50 Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol 2020;316:214-21. [PMID: 32470534 DOI: 10.1016/j.ijcard.2020.05.077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
51 Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34:966-84. [PMID: 32127639 DOI: 10.1038/s41375-020-0776-2] [Cited by in Crossref: 450] [Cited by in F6Publishing: 485] [Article Influence: 225.0] [Reference Citation Analysis]
52 Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ Jr, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020;189:363-368. [PMID: 31975387 DOI: 10.1111/bjh.16338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
53 Singh A, Decara JM. The Current and Future Role of Echocardiography for the Detection of Cardiotoxicity Related to Cancer Therapy. Curr Cardiovasc Imaging Rep 2020;13. [DOI: 10.1007/s12410-019-9523-3] [Reference Citation Analysis]
54 Link H. Chronische myeloische Leukämie: TKI-Behandlung bei hohem kardiovaskulärem Risiko. Kompass Onkol 2020;7:24-25. [DOI: 10.1159/000506301] [Reference Citation Analysis]
55 Akahoshi Y, Nakasone H, Kawamura K, Kusuda M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Gomyo A, Tanihara A, Tamaki M, Kimura S, Kako S, Kanda Y. Detection of T315I using digital polymerase chain reaction in allogeneic transplant recipients with Ph-positive acute lymphoblastic anemia in the dasatinib era. Experimental Hematology 2020;81:60-7. [DOI: 10.1016/j.exphem.2020.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
56 Bankar A, Lipton JH. Tyrosine Kinase Inhibitors in the Clinical Setting: A Conundrum of Choices. Acta Haematol 2020;143:191-3. [PMID: 31514192 DOI: 10.1159/000502472] [Reference Citation Analysis]
57 Staab J, Cotter E, Kidd B, Wallisch WJ, Flynn BC; CARE-ICU (Critical Care Anesthesia Research Enhancing ICU) Study Group. Review and Update: Hematologic Malignancies and Adult Cardiac Surgery. J Cardiothorac Vasc Anesth 2020;34:759-71. [PMID: 31447276 DOI: 10.1053/j.jvca.2019.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 García-Gutiérrez V, Hernández-Boluda JC. Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Front Oncol 2019;9:603. [PMID: 31334123 DOI: 10.3389/fonc.2019.00603] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 16.7] [Reference Citation Analysis]
59 Bencomo-Alvarez AE, Rubio AJ, Gonzalez MA, Eiring AM. Energy metabolism and drug response in myeloid leukaemic stem cells. Br J Haematol 2019;186:524-37. [PMID: 31236939 DOI: 10.1111/bjh.16074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]